298 related articles for article (PubMed ID: 30474476)
1. Efficacy and safety of PD-1 inhibitors for treating advanced melanoma: a systematic review and meta-analysis.
Li J; Gu J
Immunotherapy; 2018 Nov; 10(15):1293-1302. PubMed ID: 30474476
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of PD-1-based immunotherapy after radiologic progression on targeted therapy in stage IV melanoma.
Kreft S; Gesierich A; Eigentler T; Franklin C; Valpione S; Ugurel S; Utikal J; Haferkamp S; Blank C; Larkin J; Garbe C; Schadendorf D; Lorigan P; Schilling B
Eur J Cancer; 2019 Jul; 116():207-215. PubMed ID: 31212163
[TBL] [Abstract][Full Text] [Related]
3. Safety and Tolerability of PD-1/PD-L1 Inhibitors Compared with Chemotherapy in Patients with Advanced Cancer: A Meta-Analysis.
Nishijima TF; Shachar SS; Nyrop KA; Muss HB
Oncologist; 2017 Apr; 22(4):470-479. PubMed ID: 28275115
[TBL] [Abstract][Full Text] [Related]
4. Systematic review and meta-analysis efficacy and safety of immune checkpoint inhibitors in advanced melanoma patients with anti-PD-1 progression: a systematic review and meta-analysis.
Alrabadi NN; Abushukair HM; Ababneh OE; Syaj SS; Al-Horani SS; Qarqash AA; Darabseh OA; Al-Sous MM; Al-Aomar SR; Ahmed YB; Haddad R; Al Qarqaz FA
Clin Transl Oncol; 2021 Sep; 23(9):1885-1904. PubMed ID: 33877531
[TBL] [Abstract][Full Text] [Related]
5. Sequential treatment approaches in the management of BRAF wild-type advanced melanoma: a cost-effectiveness analysis.
Tarhini A; Benedict A; McDermott D; Rao S; Ambavane A; Gupte-Singh K; Sabater J; Ritchings C; Aponte-Ribero V; Regan MM; Atkins M
Immunotherapy; 2018 Oct; 10(14):1241-1252. PubMed ID: 30175642
[TBL] [Abstract][Full Text] [Related]
6. The role of nivolumab in melanoma.
Gomes F; Serra-Bellver P; Lorigan P
Future Oncol; 2018 Jun; 14(13):1241-1252. PubMed ID: 29328782
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials.
Larkin J; Lao CD; Urba WJ; McDermott DF; Horak C; Jiang J; Wolchok JD
JAMA Oncol; 2015 Jul; 1(4):433-40. PubMed ID: 26181250
[TBL] [Abstract][Full Text] [Related]
8. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of ipilimumab for treating advanced melanoma: A systematic review and meta-analysis.
Li J; Gu J
J Clin Pharm Ther; 2019 Jun; 44(3):420-429. PubMed ID: 30693536
[TBL] [Abstract][Full Text] [Related]
10. Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma.
Zimmer L; Apuri S; Eroglu Z; Kottschade LA; Forschner A; Gutzmer R; Schlaak M; Heinzerling L; Krackhardt AM; Loquai C; Markovic SN; Joseph RW; Markey K; Utikal JS; Weishaupt C; Goldinger SM; Sondak VK; Zager JS; Schadendorf D; Khushalani NI
Eur J Cancer; 2017 Apr; 75():47-55. PubMed ID: 28214657
[TBL] [Abstract][Full Text] [Related]
11. Nivolumab: A Review in Advanced Melanoma.
Scott LJ
Drugs; 2015 Aug; 75(12):1413-24. PubMed ID: 26220912
[TBL] [Abstract][Full Text] [Related]
12. The Efficacy and Safety of Programmed Cell Death 1 and Programmed Cell Death 1 Ligand Inhibitors for Advanced Melanoma: A Meta-Analysis of Clinical Trials Following the PRISMA Guidelines.
Guan X; Wang H; Ma F; Qian H; Yi Z; Xu B
Medicine (Baltimore); 2016 Mar; 95(11):e3134. PubMed ID: 26986169
[TBL] [Abstract][Full Text] [Related]
13. Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma.
Sznol M; Ferrucci PF; Hogg D; Atkins MB; Wolter P; Guidoboni M; Lebbé C; Kirkwood JM; Schachter J; Daniels GA; Hassel J; Cebon J; Gerritsen W; Atkinson V; Thomas L; McCaffrey J; Power D; Walker D; Bhore R; Jiang J; Hodi FS; Wolchok JD
J Clin Oncol; 2017 Dec; 35(34):3815-3822. PubMed ID: 28915085
[TBL] [Abstract][Full Text] [Related]
14. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.
Weber JS; D'Angelo SP; Minor D; Hodi FS; Gutzmer R; Neyns B; Hoeller C; Khushalani NI; Miller WH; Lao CD; Linette GP; Thomas L; Lorigan P; Grossmann KF; Hassel JC; Maio M; Sznol M; Ascierto PA; Mohr P; Chmielowski B; Bryce A; Svane IM; Grob JJ; Krackhardt AM; Horak C; Lambert A; Yang AS; Larkin J
Lancet Oncol; 2015 Apr; 16(4):375-84. PubMed ID: 25795410
[TBL] [Abstract][Full Text] [Related]
15. Risk of fatigue in cancer patients treated with anti programmed cell death-1/anti programmed cell death ligand-1 agents: a systematic review and meta-analysis.
Santoni M; Conti A; Buti S; Bersanelli M; Foghini L; Piva F; Giulietti M; Lusuardi L; Battelli N
Immunotherapy; 2018 Nov; 10(15):1303-1313. PubMed ID: 30474475
[TBL] [Abstract][Full Text] [Related]
16. The forgotten role of adjuvant immune checkpoint inhibitors in preventing melanoma brain metastasis.
El Rassy E; Farhat F; Kattan J
Immunotherapy; 2018 Nov; 10(15):1289-1291. PubMed ID: 30474477
[No Abstract] [Full Text] [Related]
17. Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma.
Ribas A; Hamid O; Daud A; Hodi FS; Wolchok JD; Kefford R; Joshua AM; Patnaik A; Hwu WJ; Weber JS; Gangadhar TC; Hersey P; Dronca R; Joseph RW; Zarour H; Chmielowski B; Lawrence DP; Algazi A; Rizvi NA; Hoffner B; Mateus C; Gergich K; Lindia JA; Giannotti M; Li XN; Ebbinghaus S; Kang SP; Robert C
JAMA; 2016 Apr; 315(15):1600-9. PubMed ID: 27092830
[TBL] [Abstract][Full Text] [Related]
18. Pembrolizumab and nivolumab: PD-1 inhibitors for advanced melanoma.
Ivashko IN; Kolesar JM
Am J Health Syst Pharm; 2016 Feb; 73(4):193-201. PubMed ID: 26843495
[TBL] [Abstract][Full Text] [Related]
19. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial.
Hodi FS; Chesney J; Pavlick AC; Robert C; Grossmann KF; McDermott DF; Linette GP; Meyer N; Giguere JK; Agarwala SS; Shaheen M; Ernstoff MS; Minor DR; Salama AK; Taylor MH; Ott PA; Horak C; Gagnier P; Jiang J; Wolchok JD; Postow MA
Lancet Oncol; 2016 Nov; 17(11):1558-1568. PubMed ID: 27622997
[TBL] [Abstract][Full Text] [Related]
20. Weighing up the pros and cons of immune checkpoint inhibitors in the treatment of melanoma.
Spain L; Larkin J
Immunotherapy; 2016 Jun; 8(6):677-9. PubMed ID: 27197536
[No Abstract] [Full Text] [Related]
[Next] [New Search]
